Old and new targets of antibacterial therapy

Journal Medical Libanais

Volumn 48, Issue 4, 2000, Pages 177-181

  Dbaibo, G S ^a  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; CECROPIN; CEPHALOSPORIN DERIVATIVE; CHLORAMPHENICOL; DEFENSIN; GENTAMICIN; GLYCOPEPTIDE; IMIPENEM; LATAMOXEF; LINEZOLID; MACROLIDE; MAGAININ DERIVATIVE; MERSACIDIN; METRONIDAZOLE; PENICILLIN DERIVATIVE; POLYPEPTIDE ANTIBIOTIC AGENT; QUINOLONE DERIVATIVE; RIFAMYCIN; STREPTOGRAMIN DERIVATIVE; SULFONAMIDE; TEICOPLANIN; TETRACYCLINE DERIVATIVE; TRIMETHOPRIM; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; BACTERIAL CELL WALL; DNA REPLICATION; DRUG EFFICACY; DRUG MECHANISM; PROTEIN SYNTHESIS; REVIEW;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; CELL WALL; DNA REPLICATION; DNA, BACTERIAL; DRUG RESISTANCE, MICROBIAL; DRUG UTILIZATION; FORECASTING; HUMANS; PATIENT SELECTION; PROTEIN SYNTHESIS INHIBITORS;

EID: 0034492030     PISSN: 00239852     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (42)

1. The crisis in antibiotic resistance
2. The structure and mode of action of glycopeptide antibiotics of the group
3. The expanding spectrum of β-lactam antibiotics
4. Beta-Lactam antibiotics (1)
5. Penicillin-binding proteins and the mechanism of action of β-lactam antibiotics
6. Imipenem : A new carbapenem antibiotic
7. Evolution and dissemination of β-lactamases accelerated by generations of β-lactam antibiotics
8. Comparative activities of the β-lactamase inhibitors YTR 830, sodium clavulanate, and sulbactam combined with amoxicillin or ampicillin
9. In vitro activity of sanfetrinem and affinity for the penicillin-binding proteins of Streptococcus pneumoniae
10. Vancomycin derivatives that inhibit peptidoglycan biosynthesis without binding D-Ala-D-Ala
11. Vancomycin, trimethoprim-sulfamethoxazole, and rifampin
12. Inhibition of transglycosylation involved in bacterial peptidoglycan synthesis
13. The lantibiotic mersacidin inhibits peptidoglycan synthesis by targeting lipid II
14. Synergy and duality in peptide antibiotic mechanisms
15. Protamine-induced permeabilization of cell envelopes of gram-positive and gram-negative bacteria
16. Molecular basis of tetracycline action : Identification of analogs whose primary target is not the bacterial ribosome
17. The mode of action of antibiotics on gram-negative bacilli
18. Tetracyclines, chloramphenicol, erythromycin, clindamycin, and metronidazole
19. Mechanism of action of spiramycin and other macrolides
20. Recent developments in macrolides and ketolides
21. Alteration of ribosomal protein L6 in gentamicin-resistant strains of Escherichia coli. Effects on fidelity of protein synthesis
22. Mutations in ribosomal protein L16 conferring reduced susceptibility to evernimicin (SCH27899) : Implications for mechanism of action
23. Aminoglycoside uptake and mode of action - With special reference to streptomycin and gentamicin. II. Effects of aminoglycosides on cells
24. Structure of the A site of Escherichia coli 16S ribosomal RNA complexed with an aminoglycoside antibiotic
25. Mechanism of action of oxazolidinones : Effects of linezolid and eperezolid on translation reactions
26. The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria
27. The molecular basis of the inhibitory activities of type A and type B synergimycins and related antibiotics on ribosomes
28. Beyond vancomycin : New therapies to meet the challenge of glycopeptide resistance
29. Antibacterials - Mechanisms of action
30. Mechanism of antimicrobial action of indolicidin
31. A detailed view of a ribosomal active site : The structure of the L11-RNA complex
32. Sulphamethoxazole-trimethoprim : The first two years
33. Trimethoprim, a sulphonamide potentiator
34. Interaction of rifamycin with bacterial RNA polymerase
35. Bacterial topoisomerases, anti-topoisomerases, and anti-topoisomerase resistance
36. Nitroimidazole drugs - Action and resistance mechanisms. I. Mechanisms of action
37. Innovative approaches to novel antibacterial drug discovery
38. Combinatorial biosynthesis for new drug discovery
39. Microbial pathogenesis : Genomics and beyond
40. New antibiotic discovery, novel screens, novel targets and impact of microbial genomics
41. Harnessing the power of the genome in the search for new antibiotics
42. Inhibition of the multiple antibiotic resistance (mar) operon in Escherichia coli by antisense DNA analogs